SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Somatogen (SMTG)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RalphLStevens,MD who wrote (421)2/26/1998 6:15:00 PM
From: CarlPerf  Read Replies (1) of 442
 
Oxygen Therapeutic marriage of the millenium:

The purchase of our beloved Somatogen by Baxter will benefit greatly future patients in need of increased oxygen carrying capacity. The majority of physicians should be excited by this new arrangement for it guaranteeds the most rapid introduction of a much needed therapeutic modality. Somatogen's Optro and its next generation mutants will be far superior to any other blood substitute firm's product. I believe Baxter will now monopolize this segment and benefit vastly from it. I am disappointed for SMTG shareholders. This company is worth twice the $9.00/sh. Unfortuantely, other major pharmaceutical firms are not intelligent enough (especially Eli Lilly) to realize this product's potential. If I were a multimillionaire, I would have bought the company. Perhaps a phonecall to Bill Gates would fetch a better price for this golden investment opportunity.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News